Novel inhibitors against wild-type and mutated HCV NS3 serine protease: an in silico study
- 21 March 2019
- journal article
- research article
- Published by Springer Nature in VirusDisease
- Vol. 30 (2) , 207-213
Abstract
In 2011, the FDA approved boceprevir as a hepatitis C virus (HCV) NS3 serine protease inhibitor. The sustained virological response rate for treatment with this approved compound is considerably low. Patients have not responded as much as expected to boceprevir therapy. In this in silico study, modified boceprevir compounds are suggested and tested on wild-type HCV NS3 protease and 19 mutated HCV NS3 proteases using molecular docking. Results reveal the superiority of two of the proposed modified compounds to boceprevir. One of which appears to be more potent than boceprevir itself concerning activity against wild-type NS3 and most of the examined mutated NS3 proteases.Keywords
This publication has 27 references indexed in Scilit:
- Structure–Activity Relationship (SAR) Development and Discovery of Potent Indole-Based Inhibitors of the Hepatitis C Virus (HCV) NS5B PolymeraseJournal of Medicinal Chemistry, 2012
- Antiviral strategies in hepatitis C virus infectionJournal of Hepatology, 2012
- Anti-HCV drugs in the pipelineCurrent Opinion in Virology, 2011
- Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitorsBioorganic & Medicinal Chemistry, 2011
- Hepatitis C virus resistance to protease inhibitorsJournal of Hepatology, 2011
- Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical speciesBioorganic & Medicinal Chemistry, 2010
- Hepatitis C virus NS3-4A serine protease inhibitors: Use of a P2–P1 cyclopropyl alanine combination for improved potencyBioorganic & Medicinal Chemistry Letters, 2005
- Announcing the worldwide Protein Data BankNature Structural & Molecular Biology, 2003
- Optimization of parameters for semiempirical methods. III Extension of PM3 to Be, Mg, Zn, Ga, Ge, As, Se, Cd, In, Sn, Sb, Te, Hg, Tl, Pb, and BiJournal of Computational Chemistry, 1991
- Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis GenomeScience, 1989